Developer of a new class of therapeutic products known as fusion toxins. These products consist of fragments of toxin fused to ligands that target specific cell surface receptors. These fused molecules are designed to (1) bind to specific receptors which are present on the surface of disease-causing or diseased cells, (2) penetrate the targeted cells and eliminate their ability to spread disease. The fusion toxins were developed using proprietary technology and have potential applications in human diseases including diseases that are either incurable or diseases for which existing therapies are of limited effect. These include cancers and autoimmune diseases such as rheumatoid arthritis and recent onset type-1 diabetes, as well as other conditions and diseases involving the immune system.